Division of Hematology and Oncology Archive — Page 10 of 16

April 30, 2020

Initiative to explore COVID-19 outcomes in cancer patients

A multi-institutional consortium led by Vanderbilt-Ingram Cancer Center (VICC) is collecting data on cancer patients with COVID-19 as part of a rapid effort to understand the unique effects the coronavirus has on this vulnerable population.

By Tom Wilemon
Close-up of a high-tech laboratory interface displaying the words “COVID-19” and “VIRUS,” with colorful circuit-like lines and data graphics.
April 23, 2020

Health workers sought for hydroxychloroquine study

Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

By Bill Snyder
red and blue boxing gloves
March 5, 2020

One-two punch for cancer

A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients.

By Sanjay Mishra
February 27, 2020

Breast cancer study may help predict treatment response

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.

By Bill Snyder
Three study leaders stand together in a laboratory, with workbenches, equipment, and a microscope visible around them. From left to right: Greg Poffenberger, Chunhua Dai, and John Walker.
February 20, 2020

Post-transplant diabetes may be reversible: study

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.

By Bill Snyder
Group of adults and a baby posing together in a laboratory beside scientific equipment.
February 13, 2020

Advocacy group’s gift boosts lung cancer research efforts

An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.

By Tom Wilemon